{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086117","form_type":"8-K","ticker":"RBOT","cik":"0001812173","company_name":"Vicarious Surgical Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.599019+00:00","generated_at":"2026-06-08T05:22:04.914116+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vicarious Surgical Q3 loss $0.10 GAAP, delays system build to Fall 2024, De Novo to 2026","bullets":["GAAP net loss $15.7M ($0.10/sh); adjusted net loss $20.4M ($0.12/sh).","Cash $110M (incl. $47M equity proceeds); Q3 cash burn $16.8M. FY23 cash burn guidance $60-65M; FY24 preliminary $40-55M.","Version 1.0 system build delayed to Fall 2024; De Novo submission now expected early-mid 2026 due to market and integration challenges.","Operating expenses $21.4M, down 4% YoY; R&D $13.0M, G&A $6.9M, S&M $1.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086117","json":"https://secwatch.observer/filing/0001213900-23-086117.json","markdown":"https://secwatch.observer/filing/0001213900-23-086117.md","text":"https://secwatch.observer/filing/0001213900-23-086117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812173/000121390023086117/0001213900-23-086117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812173/000121390023086117/ea188079-8k_vicarious.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:22:04.914116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c71e1ce833ef21390210245d340401186c91be6b","claim":"Vicarious Surgical Inc. reported the quarter ended September 30, 2023 results: net income GAAP net loss for the third quarter was $15.7 million, equating to a net loss per share of $0.10, EPS net loss per share of $0.10. Guidance reaffirmed.","evidence_excerpt":"Vicarious Surgical Reports Third Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390023086117/0001213900-23-086117-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"GAAP net loss for the third quarter was $15.7 million, equating to a net loss per share of $0.10"},{"label":"EPS","value":"net loss per share of $0.10"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}